The bone and fat connection in inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 20, Issue 11, 2014, Pages 2207-2217

  Terzoudis, Sotirios ^a   Zavos, Christos ^a   Koutroubakis, Ioannis E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Adipokines; Adiponectin; Adipose tissue; Crohn's disease; Leptin; Osteoporosis

Indexed keywords

ADIPONECTIN; CHEMERIN; GHRELIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; VASPIN;

BODY MASS; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE MINERALIZATION; CROHN DISEASE; FAT MASS; HUMAN; INFLAMMATORY BOWEL DISEASE; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; BONE DISEASES, METABOLIC; COMPLICATION; OSTEOPOROSIS; PATHOLOGY; PROGNOSIS;

ADIPOSITY; BONE DISEASES, METABOLIC; HUMANS; INFLAMMATORY BOWEL DISEASES; OSTEOPOROSIS; PROGNOSIS;

EID: 84925607670     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000111     Document Type: Review

References (166)

1. Bernstein CN. Osteoporosis in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:152-156.
2. Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12:797-813.
3. Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008;57:684-694.
4. Kim N, Kadono Y, Takami M, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med. 2005;202:589-595.
5. Li Y, Li A, Strait K, et al. Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB. J Bone Miner Res. 2007;22:646-655.
6. Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13: 791-801.
7. Epstein S, Inzerillo AM, Caminis J, et al. Disorders associated with acute rapid and severe bone loss. J Bone Miner Res. 2003;18:2083-2094.
8. Bermeo S, Gunaratnam K, Duque G. Fat and bone interactions. Curr Osteoporos Rep. 2014;12:235-242.
9. Emaus N, Wilsgaard T, Ahmed LA. Impacts of body mass Index, Physical activity, and smoking on femoral bone loss. The Tromso study. J Bone Miner Res. [published online ahead of print March 28, 2014]. doi: 10.1002/jbmr.2232.
10. Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39:724-726.
11. Guo Y, Liu H, Yang TL, et al. The fat mass and obesity associated gene, FTO, is also associated with osteoporosis phenotypes. PLoS One. 2011; 6:e27312.
12. Fischer J, Koch L, Emmerling C, et al. Inactivation of the Fto gene protects from obesity. Nature. 2009;458:894-898.
13. Campos RM, de Mello MT, Tock L, et al. Aerobic Plus resistance training improves bone metabolism and inflammation in adolescents who are obese. J Strength Cond Res. 2014;28:758-766.
14. Beresford JN, Bennett JH, Devlin C, et al. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci. 1992;102:341-351.
15. Wu J, Cohen P, Spiegelman BM. Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev. 2013;27:234-250.
16. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
17. Wu J, Bostrom P, Sparks LM, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. 2012;150:366-376.
18. Ohno H, Shinoda K, Spiegelman BM, et al. PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab. 2012;15:395-404.
19. Felson DT, Zhang Y, Hannan MT, et al. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res. 1993;8:567-573.
20. Marcus R, Greendale G, Blunt BA, et al. Correlates of bone mineral density in the postmenopausal estrogen/progestin interventions trial. J Bone Miner Res. 1994;9:1467-1476.
21. Mazess RB, Barden HS, Ettinger M, et al. Spine and femur density using dual-photon absorptiometry in US white women. Bone Miner. 1987;2: 211-219.
22. Ravn P, Cizza G, Bjarnason NH, et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res. 1999;14:1622-1627.
23. Reid IR, Ames R, Evans MC, et al. Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab. 1992;75:45-51.
24. Riis BJ, Rodbro P, Christiansen C. The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis. Calcif Tissue Int. 1986;38:318-322.
25. Hauge EM, Qvesel D, Eriksen EF, et al. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001;16:1575-1582.
26. Itoh S, Udagawa N, Takahashi N, et al. A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation. Bone. 2006;39:505-512.
27. Chen G, Deng C, Li YP. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012;8:272-288.
28. Sroga GE, Vashishth D. Effects of bone matrix proteins on fracture and fragility in osteoporosis. Curr Osteoporos Rep. 2012;10:141-150.
29. Sanford LP, Ormsby I, Gittenberger-de Groot AC, et al. TGFbeta2 knockout mice have multiple developmental defects that are nonoverlapping with other TGFbeta knockout phenotypes. Development. 1997;124:2659-2670.
30. Taya Y, O'Kane S, Ferguson MW. Pathogenesis of cleft palate in TGFbeta3 knockout mice. Development. 1999;126:3869-3879.
31. Yan X, Liu Z, Chen Y. Regulation of TGF-beta signaling by Smad7. Acta Biochim Biophys Sin (Shanghai). 2009;41:263-272.
32. He X, Semenov M, Tamai K, et al. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development. 2004; 131:1663-1677.
33. Kountouras J, Zavos C, Chatzopoulos D, et al. New aspects of Helicobacter pylori infection involvement in gastric oncogenesis. J Surg Res. 2008;146:149-158.
34. Pilpilidis I, Kountouras J, Zavos C, et al. Upper gastrointestinal carcinogenesis: H. pylori and stem cell cross-talk. J Surg Res. 2011;166: 255-264.
35. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155-192.
36. Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 1999;4: 611-617.
37. Tzameli I, Fang H, Ollero M, et al. Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J Biol Chem. 2004; 279:36093-36102.
38. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999;4: 585-595.
39. Lecka-Czernik B, Moerman EJ, Grant DF, et al. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology. 2002;143: 2376-2384.
40. Lazarenko OP, Rzonca SO, Suva LJ, et al. Netoglitazone is a PPARgamma ligand with selective effects on bone and fat. Bone. 2006;38:74-84.
41. Gimble JM, Robinson CE, Wu X, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 1996;50:1087-1094.
42. James AW. Review of signaling pathways governing MSC osteogenic and adipogenic differentiation. Scientifica (Cairo). 2013;2013:684736.
43. Aghaloo T, Cowan CM, Chou YF, et al. Nell-1-induced bone regeneration in calvarial defects. Am J Pathol. 2006;169:903-915.
44. Kawai M, Rosen CJ. The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J Cell Biochem. 2010;111:14-19.
45. Bikle D, Majumdar S, Laib A, et al. The skeletal structure of insulinlike growth factor I-deficient mice. J Bone Miner Res. 2001;16:2320-2329.
46. Fazeli PK, Horowitz MC, MacDougald OA, et al. Marrow fat and bone-new perspectives. J Clin Endocrinol Metab. 2013;98:935-945.
47. Verma S, Rajaratnam JH, Denton J, et al. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol. 2002;55:693-698.
48. Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004;35:842-849.
49. Modder UI, Roforth MM, Hoey K, et al. Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone. 2011;49:202-207.
50. Muruganandan S, Sinal CJ. The impact of bone marrow adipocytes on osteoblast and osteoclast differentiation. IUBMB Life. 2014;66:147-155.
51. Wehrli FW, Hopkins JA, Hwang SN, et al. Cross-sectional study of osteopenia with quantitative MR imaging and bone densitometry. Radiology. 2000;217:527-538.
52. Rinker TE, Hammoudi TM, Kemp ML, et al. Interactions between mesenchymal stem cells, adipocytes, and osteoblasts in a 3D tri-culture model of hyperglycemic conditions in the bone marrow microenvironment. Integr Biol (Camb). 2014;6:324-337.
53. Zulian A, Cancello R, Micheletto G, et al. Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease? Gut. 2012;61:86-94.
54. Drouet M, Dubuquoy L, Desreumaux P, et al. Visceral fat and gut inflammation. Nutrition. 2012;28:113-117.
55. Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79:955-958.
56. Fink C, Karagiannides I, Bakirtzi K, et al. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 2012; 18:1550-1557.
57. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology. 1999; 117:73-81.
58. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133:795-799.
59. Loftus EV Jr, Achenbach SJ, Sandborn WJ, et al. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1:465-473.
60. Loftus EV Jr, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002;123:468-475.
61. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol. 2002;156:1-10.
62. van Staa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003;125:1591-1597.
63. Egan E, Reilly T, Giacomoni M, et al. Bone mineral density among female sports participants. Bone. 2006;38:227-233.
64. Rector RS, Rogers R, Ruebel M, et al. Lean body mass and weightbearing activity in the prediction of bone mineral density in physically active men. J Strength Cond Res. 2009;23:427-435.
65. Bryant RV, Trott MJ, Bartholomeusz FD, et al. Systematic review: body composition in adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:213-225.
66. Thayu M, Shults J, Burnham JM, et al. Gender differences in body composition deficits at diagnosis in children and adolescents with Crohn's disease. Inflamm Bowel Dis. 2007;13:1121-1128.
67. Burnham JM, Shults J, Semeao E, et al. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am J Clin Nutr. 2005;82:413-420.
68. Wiskin AE, Wootton SA, Hunt TM, et al. Body composition in childhood inflammatory bowel disease. Clin Nutr. 2011;30:112-115.
69. Jahnsen J, Falch JA, Mowinckel P, et al. Body composition in patients with inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2003;98:1556-1562.
70. Schneider SM, Al-Jaouni R, Filippi J, et al. Sarcopenia is prevalent in patients with Crohn's disease in clinical remission. Inflamm Bowel Dis. 2008;14:1562-1568.
71. Ulivieri FM, Lisciandrano D, Ranzi T, et al. Bone mineral density and body composition in patients with ulcerative colitis. Am J Gastroenterol. 2000;95:1491-1494.
72. Cranney A, Jamal SA, Tsang JF, et al. Low bone mineral density and fracture burden in postmenopausal women. CMAJ. 2007;177:575-580.
73. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108-1112.
74. Goodhand JR, Kamperidis N, Nguyen H, et al. Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis. Aliment Pharmacol Ther. 2011;33:551-558.
75. Terzoudis S, Zavos C, Damilakis J, et al. Increased fracture risk assessed by fracture risk assessment tool in Greek patients with Crohn's disease. Dig Dis Sci. 2013;58:216-221.
76. Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273-2282.
77. Carvalheira JB, Ribeiro EB, Folli F, et al. Interaction between leptin and insulin signaling pathways differentially affects JAK-STAT and PI 3-kinase-mediated signaling in rat liver. Biol Chem. 2003;384:151-159.
78. Polyzos SA, Kountouras J, Zavos C, et al. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol. 2011;45:50-54.
79. Lo CK, Lam QL, Yang M, et al. Leptin signaling protects NK cells from apoptosis during development in mouse bone marrow. Cell Mol Immunol. 2009;6:353-360.
80. Barbier M, Vidal H, Desreumaux P, et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol. 2003;27:987-991.
81. Ballinger A, Kelly P, Hallyburton E, et al. Plasma leptin in chronic inflammatory bowel disease and HIV: implications for the pathogenesis of anorexia and weight loss. Clin Sci (Lond). 1998;94:479-483.
82. Rodrigues VS, Milanski M, Fagundes JJ, et al. Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease. Clin Exp Immunol. 2012;170:358-364.
83. Nishi Y, Isomoto H, Ueno H, et al. Plasma leptin and ghrelin concentrations in patients with Crohn's disease. World J Gastroenterol. 2005; 11:7314-7317.
84. Valentini L, Wirth EK, Schweizer U, et al. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition. 2009;25:172-181.
85. Karmiris K, Koutroubakis IE, Xidakis C, et al. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:100-105.
86. Aurangzeb B, Leach ST, Lemberg DA, et al. Assessment of nutritional status and serum leptin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:536-541.
87. Chouliaras G, Panayotou I, Margoni D, et al. Circulating leptin and adiponectin and their relation to glucose metabolism in children with Crohn's disease and ulcerative colitis. Pediatr Res. 2013;74:420-426.
88. Biesiada G, Czepiel J, Ptak-Belowska A, et al. Expression and release of leptin and proinflammatory cytokines in patients with ulcerative colitis and infectious diarrhea. J Physiol Pharmacol. 2012;63:471-481.
89. Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab. 2005;90:3510-3516.
90. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296-1301.
91. Pannacciulli N, Vettor R, Milan G, et al. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab. 2003;88: 1748-1752.
92. Yamamoto K, Kiyohara T, Murayama Y, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut. 2005;54:789-796.
93. Polyzos SA, Kountouras J, Zavos C, et al. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365-383.
94. Ajuwon KM, SpurlockME. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol. 2005;288: R1220-R1225.
95. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96:1723-1732.
96. Paul G, Schaffler A, Neumeier M, et al. Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis. 2006;12:471-477.
97. Ponemone V, Keshavarzian A, Brand MI, et al. Apoptosis and inflammation: role of adipokines in inflammatory bowel disease. Clin Transl Gastroenterol. 2010;1:e1.
98. Weigert J, Obermeier F, Neumeier M, et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Inflamm Bowel Dis. 2010;16:630-637.
99. Karmiris K, Koutroubakis IE, Xidakis C, et al. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2007;19:789-794.
100. Vihinen MK, Kolho KL, Janne OA, et al. Circulating adiponectin as a marker for glucocorticoid-related side effects in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:504-506.
101. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312.
102. Nagaev I, Bokarewa M, Tarkowski A, et al. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One. 2006;1:e31.
103. Karmiris K, Koutroubakis IE, Kouroumalis EA. The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:847-855.
104. Konrad A, Lehrke M, Schachinger V, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19:1070-1074.
105. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin-and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest. 2004;114:57-66.
106. Ariyasu H, Takaya K, Hosoda H, et al. Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. Endocrinology. 2002;143:3341-3350.
107. Peracchi M, Bardella MT, Caprioli F, et al. Circulating ghrelin levels in patients with inflammatory bowel disease. Gut. 2006;55:432-433.
108. Alexandridis E, Zisimopoulos A, Liratzopoulos N, et al. Obestatin/ghrelin ratio: a new activity index in inflammatory bowel diseases. Inflamm Bowel Dis. 2009;15:1557-1561.
109. Ates Y, Degertekin B, Erdil A, et al. Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig Dis Sci. 2008;53:2215-2221.
110. Sung EZ, Da Silva NF, Goodyear S, et al. Increased plasma ghrelin following infliximab in Crohn's disease. Aliment Pharmacol Ther. 2009;29:83-89.
111. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-1792.
112. Yamaguchi N, Kukita T, Li YJ, et al. Adiponectin inhibits osteoclast formation stimulated by lipopolysaccharide from Actinobacillus actinomycetemcomitans. FEMS Immunol Med Microbiol. 2007;49:28-34.
113. Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005;331:520-526.
114. Williams GA, Wang Y, Callon KE, et al. In vitro and in vivo effects of adiponectin on bone. Endocrinology. 2009;150:3603-3610.
115. Lee HW, Kim SY, Kim AY, et al. Adiponectin stimulates osteoblast differentiation through induction of COX2 in mesenchymal progenitor cells. Stem Cells. 2009;27:2254-2262.
116. Reid IR. Fat and bone. Arch Biochem Biophys. 2010;503:20-27.
117. Lenchik L, Register TC, Hsu FC, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003;33:646-651.
118. Richards JB, Valdes AM, Burling K, et al. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab. 2007;92: 1517-1523.
119. Napoli N, Pedone C, Pozzilli P, et al. Adiponectin and bone mass density: the InCHIANTI study. Bone. 2010;47:1001-1005.
120. Jurimae J, Rembel K, Jurimae T, et al. Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res. 2005; 37:297-302.
121. Shinoda Y, Yamaguchi M, Ogata N, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem. 2006;99:196-208.
122. Chang CJ, Yen ML, Chen YC, et al. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells. 2006;24:2466-2477.
123. Thomas T, Gori F, Khosla S, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999;140:1630-1638.
124. Yang DC, Tsay HJ, Lin SY, et al. cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. PLoS One. 2008;3:e1540.
125. Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269:546-549.
126. Iwaniec UT, Wronski TJ, Amblard D, et al. Effects of disrupted beta1-integrin function on the skeletal response to short-term hindlimb unloading in mice. J Appl Physiol (1985). 2005;98:690-696.
127. Otukonyong EE, Dube MG, Torto R, et al. Central leptin differentially modulates ultradian secretory patterns of insulin, leptin and ghrelin independent of effects on food intake and body weight. Peptides. 2005;26: 2559-2566.
128. Laharrague P, Larrouy D, Fontanilles AM, et al. High expression of leptin by human bone marrow adipocytes in primary culture. FASEB J. 1998;12:747-752.
129. Hamrick MW, Della-Fera MA, Choi YH, et al. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptindeficient ob/ob mice. J Bone Miner Res. 2005;20:994-1001.
130. Steppan CM, Crawford DT, Chidsey-Frink KL, et al. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept. 2000;92:73-78.
131. Martin A, de Vittoris R, David V, et al. Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tailsuspended female rats. Endocrinology. 2005;146:3652-3659.
132. Burguera B, Hofbauer LC, Thomas T, et al. Leptin reduces ovariectomyinduced bone loss in rats. Endocrinology. 2001;142:3546-3553.
133. Martin A, David V, Malaval L, et al. Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulinlike growth factor-I pathway. Endocrinology. 2007;148:3419-3425.
134. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999; 341:879-884.
135. Tamura T, Yoneda M, Yamane K, et al. Serum leptin and adiponectin are positively associated with bone mineral density at the distal radius in patients with type 2 diabetes mellitus. Metabolism. 2007;56:623-628.
136. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351:987-997.
137. Morberg CM, Tetens I, Black E, et al. Leptin and bone mineral density: a cross-sectional study in obese and nonobese men. J Clin Endocrinol Metab. 2003;88:5795-5800.
138. Koutroubakis IE, Zavos C, Damilakis J, et al. Role of ghrelin and insulin-like growth factor binding protein-3 in the development of osteoporosis in inflammatory bowel disease. J Clin Gastroenterol. 2011;45: e60-e65.
139. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003;300:472-476.
140. Geerling BJ, Lichtenbelt WD, Stockbrugger RW, et al. Gender specific alterations of body composition in patients with inflammatory bowel disease compared with controls. Eur J Clin Nutr. 1999;53:479-485.
141. Thommesen L, Stunes AK, Monjo M, et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem. 2006;99:824-834.
142. Zhang H, Xie H, Zhao Q, et al. Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. J Endocrinol Invest. 2010;33:707-711.
143. Fisher A, Southcott E, Li R, et al. Serum resistin in older patients with hip fracture: relationship with comorbidity and biochemical determinants of bone metabolism. Cytokine. 2011;56:157-166.
144. Wang DH, Hu YS, Du JJ, et al. Ghrelin stimulates proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway. Endocrine. 2009;35:112-117.
145. Liang QH, Liu Y, Wu SS, et al. Ghrelin inhibits the apoptosis of MC3T3-E1 cells through ERK and AKT signaling pathway. Toxicol Appl Pharmacol. 2013;272:591-597.
146. Deng F, Ling J, Ma J, et al. Stimulation of intramembranous bone repair in rats by ghrelin. Exp Physiol. 2008;93:872-879.
147. Nouh O, Abd Elfattah MM, Hassouna AA. Association between ghrelin levels and BMD: a cross sectional trial. Gynecol Endocrinol. 2012;28: 570-572.
148. Gonnelli S, Caffarelli C, Del Santo K, et al. The relationship of ghrelin and adiponectin with bone mineral density and bone turnover markers in elderly men. Calcif Tissue Int. 2008;83:55-60.
149. Amini P, Cahill F, Wadden D, et al. Beneficial association of serum ghrelin and peptide YY with bone mineral density in the Newfoundland population. BMC Endocr Disord. 2013;13:35.
150. Napoli N, Pedone C, Pozzilli P, et al. Effect of ghrelin on bone mass density: the In Chianti study. Bone. 2011;49:257-263.
151. Xie H, Tang SY, Luo XH, et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int. 2007;80:201-210.
152. Moschen AR, Geiger S, Gerner R, et al. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res. 2010;690:95-101.
153. Peng XD, Xie H, Zhao Q, et al. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta. 2008;387: 31-35.
154. Tohidi M, Akbarzadeh S, Larijani B, et al. Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal women. Bone. 2012;51:876-881.
155. Iacobellis G, Iorio M, Napoli N, et al. Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest. 2011;34:e12-e15.
156. Terzoudis S, Malliaraki N, Damilakis I, et al. P268 Chemerin, visfatin and vaspin levels in relation to fat mass and bone mineral density in IBD. J Crohn's Colitis. 2014;8:S175.
157. Kamio N, Kawato T, Tanabe N, et al. Vaspin attenuates RANKLinduced osteoclast formation in RAW264.7 cells. Connect Tissue Res. 2013;54:147-152.
158. Zhu X, Jiang Y, Shan PF, et al. Vaspin attenuates the apoptosis of human osteoblasts through ERK signaling pathway. Amino Acids. 2013;44: 961-968.
159. Wittamer V, Bondue B, Guillabert A, et al. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol. 2005;175:487-493.
160. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977-985.
161. Zabel BA, Allen SJ, Kulig P, et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem. 2005;280:34661-34666.
162. Muruganandan S, Roman AA, Sinal CJ. Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J Bone Miner Res. 2010;25:222-234.
163. Geerling BJ, Badart-Smook A, Stockbrugger RW, et al. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr. 2000;54: 514-521.
164. Ulivieri FM, Piodi LP, Taioli E, et al. Bone mineral density and body composition in ulcerative colitis: a six-year follow-up. Osteoporos Int. 2001;12:343-348.
165. Leslie WD, Miller N, Rogala L, et al. Body mass and composition affect bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Inflamm Bowel Dis. 2009;15:39-46.
166. Cuoco L, Vescovo G, Castaman R, et al. Skeletal muscle wastage in Crohn's disease: a pathway shared with heart failure? Int J Cardiol. 2008;127:219-227.